[1]卢钰琼,代展菁,路 云,等.健康状态效用值测量研究报告规范及对比研究[J].卫生经济研究,2022,39(7):68-73.
　LU Yuqiong,DAI Zhanjing,LU Yun,et al.Reporting Guidelines for and Comparative Study of Health State Utility Values Estimation[J].Journal Press of Health Economics Research,2022,39(7):68-73.
点击复制

健康状态效用值测量研究报告规范及对比研究
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
39
期数:
2022年7期
页码:
68-73
栏目:
健康管理
出版日期:
2022-06-30

文章信息/Info

Title:
Reporting Guidelines for and Comparative Study of Health State Utility Values Estimation
作者:
卢钰琼1; 代展菁1; 路 云1; 常 峰1
1.中国药科大学国际医药商学院，江苏 南京211198
Author(s):
LU Yuqiong;  DAI Zhanjing;  LU Yun;  CHANG Feng
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing Jiangsu 211198, China
关键词:
健康状态效用值; 经济学评价; 报告规范
Keywords:
health state utility values (HSUVs);  economic evaluation;  reporting guideline
分类号:
R19
文献标志码:
A
摘要:
目的：比较研究国际上权威机构开发的健康状态效用值（HSUVs）测量研究报告规范，为我国开展HSUVs测量研究提供报告规范参考。方法：基于国内外文献，梳理4个HSUVs测量研究报告规范的发展历史及应用情况，对其适用范围和条目内容进行比较分析。结果：4个HSUVs测量研究报告规范的开发目的不同，适用范围不同，条目内容的侧重点也有所不同；HSUVs测量研究报告规范清单须包含5个方面16个条目。结论：在开展HSUVs测量研究时，应根据研究主题参考合适的规范，也可联合使用多种报告规范。
Abstract:
Objective To study reporting guidelines for the health state utility values (HSUVs) estimation for advancing the standardization of the implementation and reporting of HSUVs estimation. Methods This study summarized the development history and application of four reporting guidelines, and compared their applicable conditions and specific items. Results These four guidelines showed differences in their goals, applicable conditions, and focus of specific items. These indicated that a checklist of reporting guidelines for HSUVs estimation should contain 5 aspects and 16 items. Conclusions It is suggested to adopt suitable guideline according to study aims. A joint use of different guidelines is also advocated.

参考文献/References:

[1] Wolowacz S E，Briggs A,Belozeroff V,e al.Estimating health-state utility for economic models in clinical studies：an ISPOR good research practices task force report[J].Value in Health,2016,19(6)：704-719.
[2] 伍红艳.健康效用值测量研究[D].沈阳：沈阳药科大学，2012.
[3] 刘国恩主编.国药物经济学评价指南（2020版）[M].北京：中国市场出版社，2020.
[4] 余正，段君军，王海兵，等.成本效用分析文献中效用值的来源分析[J].卫生经济研究，2016（8）：52-54.
[5] Brazier J,Deverill M.A checklist for judging preference-based measures of health related quality of life：learning from psychometrics[J].Health Economics,1999,8(1)：41-51.
[6] Cooper N,Coyle D，Abrams K,et al.Use of evidence in decision models：an appraisal of health technology assessments in the UK since 1997[J].Journal of Health Services Research & Policy,2005,10(4)：245-250.
[7] Lancsar E,Louviere J.Conducting discrete choice experiments to inform healthcare decision making[J].Pharmacoeconomics,2008,26(8)：661-677.
[8] Papaioannou D,Brazier J，Paisley S.NICE DSU Technical Support Document 9：the identification，review and synthesis of health state utility values from the literature[Z].Sheffield：NICE Decision Support Unit,University of Sheffield,2010.
[9] Papaioannou D,Brazier J,Paisley S.Systematic searching and selection of health state utility values from the literature[J].Value in Health,2013,16(4)：686-695.
[10] Ara R,Brazier J,Peasgood T，et al.The identification， review and synthesis of health state utility values from the literature[J].Pharmacoeconomics,2017,35(1)：43-55.
[11] Buchanan-Hughes A M,Buti M,Hanman K,et al.Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C：a systematic literature review and meta-analysis[J].Quality of Life Research,2019,28(2)：297-319.
[12] Watson C,Tallentire C W,Ramage J K,et al.Quality of life in patients with gastroenteropancreatic tumours：A systematic literature review[J].World Journal of Gastroenterology, 2020,26(25)：3686.
[13] Mok C H,Kwok H H Y,Ng C S,et al.Health State Utility Values for Type 2 Diabetes and Related Complications in East and Southeast Asia：A Systematic Review and Meta-Analysis[J].Value in Health,2021.
[14] Meregaglia M,Cairns J.A systematic literature review of health state utility values in head and neck cancer[J].Health and Quality of Life Outcomes,2017,15(1)：1-13.
[15] Bridges J F P,Hauber A B,Marshall D,et al.Conjoint analysis applications in health-a checklist：a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force[J].Value in Health,2011,14(4)：403-413.
[16] Janssen E M,Hauber A B,Bridges J F P.Conducting a discrete-choice experiment study following recommendations for good research practices：an application for eliciting patient preferences for diabetes treatments[J].Value in Health,2018,21(1)：59-68.
[17] Beusterien K,Grinspan J,Kuchuk I,et al.Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects[J].The Oncologist,2014,19(2)：127.
[18] Stein E M,Yang M,Guerin A,et al.Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States[J].Health and Quality of Life Outcomes,2018,16(1)：1-12.
[19] Wortley S,Wong G,Kieu A,et al.Assessing stated preferences for colorectal cancer screening：a critical systematic review of discrete choice experiments[J].The Patient-Patient-Centered Outcomes Research,2014,7(3)：271-282.
[20] Joy S M,Little E,Maruthur N M,et al.Patient preferences for the treatment of type 2 diabetes：a scoping review[J].Pharmacoeconomics,2013,31(10)：877-892.
[21] Hauber A B,González J M,Groothuis-Oudshoorn C G M,et al. Statistical methods for the analysis of discrete choice experiments：a report of the ISPOR Conjoint Analysis Good Research Practices Task Force[J].Value in Health,2016,19(4)：300-315.
[22] Matza L S,Stewart K D，Lloyd A J,et al.Vignette-based utilities：usefulness,limitations，and methodological recommendations[J].Value in Health,2021,24(6)：812-821.
[23] Rowen D,Brazier J,Wong R,et al.Measuring and valuing health-related quality of life when sufficient EQ-5D data is not available[J].Report by the Decision Support Unit,2020.

相似文献/References:

[1]于保荣,许 晴,刘 卓,等.新发传染病经济负担的方法学研究[J].卫生经济研究,2017,(07):25.
[2]田 磊,赵昕锐,李洪超.我国肿瘤免疫治疗经济学评价研究现状与挑战[J].卫生经济研究,2021,38(1):35.
　TIAN Lei,ZHAO Xin-rui,LI Hong-chao.Research Status and Challenge of Economic Evaluation of Tumor Immunotherapy in China[J].Journal Press of Health Economics Research,2021,38(7):35.
[3]朱 宏,黄鸿燕,郑胄斌,等.日间手术的经济学评价研究综述[J].卫生经济研究,2021,38(9):25.
　ZHU Hong,ZHENG Zhou-bin,HUANG Hong-yan,et al.Overview on Day Operation Economic Evaluation Research[J].Journal Press of Health Economics Research,2021,38(7):25.
[4]于保荣,孔维政,王 庆.普惠险药品准入机制与评估体系研究[J].卫生经济研究,2022,39(8):1.
　YU Baorong,KONG Weizheng,WANG Qing.Research on Access Mechanism and Evaluation System of Inclusive Insurance Drugs[J].Journal Press of Health Economics Research,2022,39(7):1.
[5]汤雅倩,赵明烨,唐文熙.信迪利单抗对比卡瑞利珠单抗一线治疗 晚期非鳞状非小细胞肺癌的经济学评价[J].卫生经济研究,2023,40(2):34.
　TANG Yaqian,ZHAO Mingye,TANG Wenxi.Pharmacoeconomic Evaluation of Sintilimab Versus Camrelizumab in the First-Line Treatment of Patients with Non-Squamous Advanced Non-Small Cell Lung Cancer in China[J].Journal Press of Health Economics Research,2023,40(7):34.
[6]湛浩然,胡玉瑶,孙雨馨,等.分布式成本效果评价方法及研究现状[J].卫生经济研究,2023,40(9):85.
　ZHAN Haoran,HU Yuyao,SUN Yuxin,et al.Introduction and Application Status of Distributional Cost-effectiveness Analysis[J].Journal Press of Health Economics Research,2023,40(7):85.

更新日期/Last Update: 2022-06-30